D-Glutamine

Patient education, lifestyle modifications, and medication review are crucial for managing priapism in sickle cell disease (SCD). Alpha-adrenergic agonists like etilefrine and phosphodiesterase type 5 inhibitors (PDE5i) are used to treat SCD-related priapism. Hormonal manipulation with cyproterone acetate, 5-α reductase inhibitors, ketoconazole, and diethylstilbestrol shows limited efficacy. Hydroxyurea, red cell exchange therapy, crizanlizumab, voxelotor, and L-glutamine offer potential benefits but lack specific trials for priapism. Allogeneic hematopoietic stem cell transplantation and gene therapy are curative options with ongoing research.

Etavopivat reduced annualized vaso-occlusive crises rate vs. placebo in sickle cell disease, increased hemoglobin levels, reduced fatigue, and improved hemolysis markers, according to HIBISCUS trial data presented at ASH Annual Meeting and Exposition.

Symmetry considerations and microscopic features affect Josephson coupling in SCs, with bulk current vanishing under certain conditions. Edge contributions dominate when bulk coupling is symmetry-forbidden, providing a phase-sensitive probe of SC order parameters.

The study involved ethical approval, leukapheresis for NK cell production, and adherence to GMP regulations. NK cells were manufactured using CliniMACS Prodigy, with quality control including sterility testing, cell count, and viability analysis. Cell lines and primary NK cells were isolated and cultured for cytotoxicity and degranulation assays.

The FDA granted orphan drug status to Kind Pharmaceuticals' AND017 for treating sickle cell disease, offering incentives like tax credits and market exclusivity. AND017, which inhibits HIF-PH to boost red blood cell production, showed promising safety and efficacy in preclinical studies and Phase 1 trials, and is also being developed for anemia in other conditions.

The FDA granted orphan drug designation to AND017 for sickle cell disease, with preclinical data to be presented. Phase 1 and 2 trials showed AND017's safety and efficacy in treating anemia in chronic kidney disease patients. AND017, a first-in-class hemoglobin elevating agent, is also being developed for cancer-related anemia, myelodysplastic syndes, and β-thalassemia.

Peter Edwards and Christina launch their solo gospel albums, 'Holy One' and 'It is Jesus,' at Double Impact event on Nov 16 in Ontario. Both albums feature collaborations and are aimed at youth and non-believers.

Kind Pharmaceutical's AND017 receives FDA Orphan Drug Designation for Sickle Cell Disease, aiming to treat anemia in chronic kidney disease and other conditions. The designation highlights the urgent need for new therapies and Kind's innovation capability.

The FDA granted Orphan Drug Designation to AND017 for treating sickle cell disease (SCD), affecting 120,000 US patients. AND017, a first-in-class hemoglobin elevating agent, aims to offer a novel oral treatment with better safety and efficacy than current options. It targets multiple stages of red blood cell life cycle and is under development for various anemia indications. Clinical trial results are presented at the 2024 ASN Kidney Week, with preclinical SCD data planned for future presentation.

Pfizer withdraws Oxbryta (voxelotor) for sickle cell disease from all markets due to imbalance in vaso-occlusive crises and fatal events, discontinuing all clinical trials and expanded access program.